All In Biotech

Drug Trial Radar · NCT01095796

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Last checked: Nov 19, 2026Latest source record: Nov 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 707 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

707

Actual

Start

Mar 2010

Primary completion

Aug 2011

Study completion Sep 2014

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 30, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of Stribild®, a single tablet regimen (STR) containing fixed doses of elvitegravir (EVG)/cobicistat (COBI \[GS-9350\])/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) versus efavirenz (EFV)/FTC/TDF (Atripla®) in HIV-1 infected, antiretroviral treatment-naive adults. Stribild offers an alternative STR for patients who are not candidates for non-nucleoside reverse transcriptor-based STRs.

Conditions

  • HIV
  • HIV Infections

Interventions

  • StribildDrug

    Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily

  • AtriplaDrug

    Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime

  • Stribild PlaceboDrug

    Placebo to match Stribild STR administered orally once daily

  • Atripla PlaceboDrug

    Placebo to match Atripla tablet administered orally once daily prior to bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48Time frame: Week 48

Locations

102 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Spectrum Medical Group

    Phoenix, Arizona

  • Health for Life Clinic PLLC

    Little Rock, Arkansas

  • AHF Research Center

    Beverly Hills, California

  • Kaiser Permanente Hospital

    Hayward, California

  • Living Hope Clinical Foundation

    Long Beach, California

  • Kaiser Permanente

    Los Angeles, California

  • Los Angeles Gay and Lesbian Center DBA Jeffrey Goodman Special Care Clinic

    Los Angeles, California

  • UCLA Center for Clinical Aids Research and Education

    Los Angeles, California

  • Peter J. Ruane, MD, Inc.

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Anthony Mills, MD, Inc.

    Los Angeles, California

  • Orange Coast Medical Group

    Newport Beach, California

  • Alameda County Medical Center

    Oakland, California

  • East Bay AIDS Center

    Oakland, California

  • Stanford University

    Palo Alto, California

  • Kaiser Permanente Medical Group

    Sacramento, California

  • La Playa Medical Group and Clinical Research

    San Diego, California

  • San Francisco General Hospital, University of California, San Francisco

    San Francisco, California

  • Metropolis Medical

    San Francisco, California

  • Kaiser Permanente Medical Center, Clinical Trials Unit

    San Francisco, California

  • Apex Research, LLC

    Denver, Colorado

  • Yale University HIV Clinical Trials Program

    New Haven, Connecticut

  • The Stamford Hospital

    Stamford, Connecticut

  • Dupont Circle Physicians Group

    Washington D.C., District of Columbia

  • Whitman-Walker Clinic

    Washington D.C., District of Columbia

  • Capital Medical Associates, PC

    Washington D.C., District of Columbia

  • George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia

  • Therafirst Medical Center

    Fort Lauderdale, Florida

  • Broward Health/Comprehensive Care Center

    Fort Lauderdale, Florida

  • Gary J. Richmond, MD, PA

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • The Kinder Medical Group

    Miami, Florida

  • University of Miami School of Medicine

    Miami, Florida

  • Wohlfeiler, Piperato and Associates, LLC

    Miami Beach, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Idocf/ Valuhealthmd, Llc

    Orlando, Florida

  • University of South Florida HIV Clinical Research Unit / Hillsborough County Health Department

    Tampa, Florida

  • Infectious Disease Research Institute Inc.

    Tampa, Florida

  • St. Joseph's Comprehensive Research Institute

    Tampa, Florida

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.